Translational Lung Cancer Research,
Год журнала:
2023,
Номер
0(0), С. 0 - 0
Опубликована: Янв. 1, 2023
Lung
cancer
is
the
most
common
in
world,
and
non-small
cell
lung
(NSCLC)
constitutes
about
80-85%.
In
this
phase
III
trial,
we
evaluate
efficacy
safety
of
anti-programmed
death-1
(PD-1)
monoclonal
antibody
(SCT-I10A)
plus
docetaxel
compared
to
patients
with
previously
treated
advanced
squamous
NSCLC
(sqNSCLC).
Patients
were
randomized
2:1
finotonlimab
group
(finotonlimab
docetaxel)
(placebo
for
up
6
cycles,
followed
by
maintenance
monotherapy
finotonlimab/placebo.
The
primary
endpoint
was
overall
survival
(OS).
Secondary
endpoints
included
objective
response
rate
(ORR),
disease
control
(DCR),
duration
(DoR),
progression-free
(PFS)
as
well
assessments
immunogenicity.
There
188
eligible
enrolled
group:
n=126;
n=62).
Median
OS
(mOS)
17.1
months
[95%
confidence
interval
(CI):
11.2,
20.0]
10.4
(95%
CI:
5.9,
14.0)
group.
Hazard
ratio
(HR)
0.66
0.45,
0.96;
P=0.03).
PFS
(mPFS)
4.2
3.3,
6.9)
2.9
1.5,
3.8)
respectively
achieved
an
ORR
27.0%
19.5%,
35.6%),
which
significantly
higher
than
3.2%
0.4%,
11.2%)
DCR
68.3%
59.4%,
76.3%)
56.5%
43.3%,
69.0%)
Treatment-related
adverse
events
(TRAEs)
occurred
91.3%
(115/126)
87.1%
(54/62)
SCT-I10A
combined
prolonged
improved
clinical
outcomes
sqNSCLC
docetaxel,
without
increasing
risk.
NCT04171284,
ClinicalTrials.gov.
Clinical Medicine Insights Oncology,
Год журнала:
2025,
Номер
19
Опубликована: Янв. 1, 2025
Background:
This
study
systematically
assesses
the
efficacy
of
immunotherapy
as
a
first-line
treatment
for
patients
with
non-small-cell
lung
cancer
(NSCLC)
and
bone
metastases
who
lack
driver
gene
mutations.
analysis
draws
on
data
from
randomized
controlled
trials
to
support
individualized
strategies.
Methods:
Randomized
published
up
October
1,
2024,
were
retrieved
PubMed,
EMBASE,
Cochrane
Library,
Web
Science.
Statistical
analyses
conducted
using
RevMan
5.4
STATA
17.0,
results
presented
in
forest
plots.
Progression-free
survival
(PFS)
overall
(OS)
analyzed
hazard
ratios
(HRs)
corresponding
95%
confidence
intervals
(CIs).
was
registered
International
Prospective
Register
Systematic
Reviews
(PROSPERO)
(CRD42024604768).
Results:
Meta-analysis
demonstrated
significant
improvement
OS
PFS
receiving
(OS:
HR:
0.81,
CI:
0.71-0.92;
PFS:
0.78,
0.62-0.98).
Although
benefit
lower
than
those
without,
it
superior
chemotherapy.
Conclusions:
Among
gene-negative
NSCLC
metastases,
significantly
improved
PFS,
thus
supporting
its
role
an
effective
treatment.
Further
large-scale
are
recommended
enhance
precision
validate
these
findings.
EMJ Oncology,
Год журнала:
2024,
Номер
unknown, С. 39 - 48
Опубликована: Окт. 29, 2024
The
metastatic
non-small
cell
lung
cancer
(mNSCLC)
treatment
landscape
has
vastly
expanded
over
the
past
two
decades
as
a
result
of
advancements
in
biomarker
testing.
However,
unmet
needs
remain
both
terms
options
for
some
patient
groups,
and
support
throughout
journey.
In
this
symposium,
Jarushka
Naidoo,
Consultant
Medical
Oncologist,
Beaumont
RCSI
Cancer
Centre,
Dublin,
Ireland;
Terri
Conneran,
KRAS
Kickers,
Charlotte,
North
Carolina,
USA;
Luis
Paz-Ares,
Chair
Oncology
Department,
Hospital
Universitario
12
de
Octubre,
Madrid,
Spain;
Alexander
Drilon,
Chief
Early
Drug
Development
Thoracic
Oncology,
Memorial
Sloan
Kettering
Center,
New
York,
USA,
focused
on
patient-centric
approaches
to
mNSCLC
treatment,
starting
with
advocacy
group
perspective
what
patients
want
from
their
care
team
during
panel
also
discussed
immuno-oncology
(I-O)
monotherapy
combination
therapy,
including
dual
I-O
therapies
programmed
death-ligand
1
(PD-L1)
tumour
expression
<1%,
well
KRASG12C-mutated
mNSCLC,
ongoing
trials
KRAS-targeted
agents.
addition,
latest
data
tyrosine
kinase
inhibitors
(TKI)
alterations
ROS1
NTRK
genes
were
discussed,
focusing
next-generation
TKIs.
Finally,
cases,
taking
into
account
specific
considerations
how
best
approach
decisions.
Translational Lung Cancer Research,
Год журнала:
2023,
Номер
0(0), С. 0 - 0
Опубликована: Янв. 1, 2023
Lung
cancer
is
the
most
common
in
world,
and
non-small
cell
lung
(NSCLC)
constitutes
about
80-85%.
In
this
phase
III
trial,
we
evaluate
efficacy
safety
of
anti-programmed
death-1
(PD-1)
monoclonal
antibody
(SCT-I10A)
plus
docetaxel
compared
to
patients
with
previously
treated
advanced
squamous
NSCLC
(sqNSCLC).
Patients
were
randomized
2:1
finotonlimab
group
(finotonlimab
docetaxel)
(placebo
for
up
6
cycles,
followed
by
maintenance
monotherapy
finotonlimab/placebo.
The
primary
endpoint
was
overall
survival
(OS).
Secondary
endpoints
included
objective
response
rate
(ORR),
disease
control
(DCR),
duration
(DoR),
progression-free
(PFS)
as
well
assessments
immunogenicity.
There
188
eligible
enrolled
group:
n=126;
n=62).
Median
OS
(mOS)
17.1
months
[95%
confidence
interval
(CI):
11.2,
20.0]
10.4
(95%
CI:
5.9,
14.0)
group.
Hazard
ratio
(HR)
0.66
0.45,
0.96;
P=0.03).
PFS
(mPFS)
4.2
3.3,
6.9)
2.9
1.5,
3.8)
respectively
achieved
an
ORR
27.0%
19.5%,
35.6%),
which
significantly
higher
than
3.2%
0.4%,
11.2%)
DCR
68.3%
59.4%,
76.3%)
56.5%
43.3%,
69.0%)
Treatment-related
adverse
events
(TRAEs)
occurred
91.3%
(115/126)
87.1%
(54/62)
SCT-I10A
combined
prolonged
improved
clinical
outcomes
sqNSCLC
docetaxel,
without
increasing
risk.
NCT04171284,
ClinicalTrials.gov.
